Time Course of Postprandial Protein Metabolism

Sponsor

University of Illinois at Urbana-Champaign (Other)

Overall Status

Completed

CT.gov ID

NCT04121689

Collaborator

(none)

Enrollment

Location

Arm

58.8

Actual Duration (Months)

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The anabolic action of 'fast' whey protein on the regulation of postprandial muscle protein synthesis has been established to be short-lived in healthy young adults. Our aim was assess the time course of anabolic signaling events and stimulation of muscle protein synthesis rates (MPS) after ingestion of a food source that represents a more typical meal-induced pattern of aminoacidemia, namely milk protein concentrate, in healthy young males.

Condition or Disease	Intervention/Treatment	Phase
Muscle Protein Synthesis Protein Metabolism	Dietary Supplement: Milk Protein Concentrate	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

7 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

Time-dependent Regulation of Postprandial Muscle Protein Synthesis After Milk Protein Ingestion in Young Men

Actual Study Start Date :

Oct 1, 2014

Actual Primary Completion Date :

Nov 1, 2014

Actual Study Completion Date :

Aug 26, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Milk Protein Concentrate Seven young men (age: 22±1 y) will undergo repeated blood and biopsy sampling during primed continuous L-[ring-2H5]phenylalanine and L-[1-13C]leucine tracer infusions, and ingested 38 g of L-[1-13C]phenylalanine- and L-[1-13C]leucine-labeled milk protein concentrate	Dietary Supplement: Milk Protein Concentrate The macronutrient composition and energy of the milk protein beverage provided to participants is 38 g protein (3.46 g leucine), 4.17 g carbohydrate, and 1.4 g fat. The milk protein met all chemical and bacteriologic specifications for human consumption. The L-[1-13C]phenylalanine and L-[1-13C]leucine enrichments in the milk protein concentrate averaged 38.3 and 10.8 mole percent excess (MPE), respectively.

Arm

Intervention/Treatment

Experimental: Milk Protein Concentrate

Seven young men (age: 22±1 y) will undergo repeated blood and biopsy sampling during primed continuous L-[ring-2H5]phenylalanine and L-[1-13C]leucine tracer infusions, and ingested 38 g of L-[1-13C]phenylalanine- and L-[1-13C]leucine-labeled milk protein concentrate

Dietary Supplement: Milk Protein Concentrate

The macronutrient composition and energy of the milk protein beverage provided to participants is 38 g protein (3.46 g leucine), 4.17 g carbohydrate, and 1.4 g fat. The milk protein met all chemical and bacteriologic specifications for human consumption. The L-[1-13C]phenylalanine and L-[1-13C]leucine enrichments in the milk protein concentrate averaged 38.3 and 10.8 mole percent excess (MPE), respectively.

Outcome Measures

Primary Outcome Measures

Fractional synthesis rates of myofibrillar protein [8 hours]
Myofibrillar protein synthesis rates will be assessed during the postabsorptive period for 3 hours, and every 1-2 hours during the 5 hours after protein ingestion. This will allow us assess the timecourse of muscle protein synthesis after eating.

Secondary Outcome Measures

Phosphorylation of muscle anabolic signaling [8 hours]
Phosphorylation of anabolic signaling pathways (mTORC1, AKT, and P70S6K) involved in the stimulation of myofibrillar protein synthesis rates will be assessed during the postabsorptive period for 3 hours, and every 1-2 hours during the 5 hours after protein ingestion.
Exogenous rate of phenylalanine appearance [5 hours]
Dietary derived phenylalanine availability will be measured during the 5 h postprandial phase to determine its relationship with the fractional synthesis rates of myofibrillar protein and phosphorylation of muscle anabolic signaling

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 35 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Yes

Inclusion criteria

Males
Aged between 18-35 years
Healthy, recreationally active
BMI < 30 kg/m2

Exclusion criteria

Smoking
Allergies to milk proteins
Vegetarians
Diagnosed GI tract diseases
Female
Arthritic conditions
A history of neuromuscular problems
Previous participation in amino acid tracer studies
Predisposition to hypertrophic scarring or keloid formation
Individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Freer Hall	Urbana	Illinois	United States	61801

Sponsors and Collaborators

University of Illinois at Urbana-Champaign

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

University of Illinois at Urbana-Champaign

ClinicalTrials.gov Identifier:

NCT04121689

Other Study ID Numbers:

14234

First Posted:

Oct 10, 2019

Last Update Posted:

Oct 10, 2019

Last Verified:

Aug 1, 2019

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by University of Illinois at Urbana-Champaign

Additional relevant MeSH terms:

Caseins

Study Results

No Results Posted as of Oct 10, 2019